INS and Hypoglycemia: Although traditional hypoglycemic drugs such as insulin and sulfonylureas can control blood glucose in the short term, they generally have limitations such as weight gain and increased risk of hypoglycemia, making it difficult to meet the clinical needs of “comprehensive metabolic management” for T2DM (Bailey et al., 2016).